LONDON, June 11 (Reuters) - Roche's cancer drug Avastin is a cheap, effective treatment for preventing blindness and should be used routinely in countries that cannot afford the far more costly ...

ZURICH/LONDON (Reuters) - Roche , trying to get back on its feet after a dismal year, could soon face a new blow if its top cancer drug Avastin proves to be a viable cut-price alternative to Lucentis ...

Even without an FDA approval, Roche’s cancer drug Avastin is widely used by doctors to treat certain eye diseases. Outlook Therapeutics has been trying to get an official approval for a reformulated ...

The FDA has issued an alert that repackaged intravitreal injections of the drug Avastin have caused at least a dozen serious eye infections in the Miami area, according to an FDA news release. The ...

Due to a shortage of a widely used compounded medicine for serious eye diseases, two leading ophthalmologic groups want Medicare contractors to halt practices that limit coverage of other — albeit ...

One option for macular degeneration cuts treatment costs from $2,000 to $50. April 4, 2011— -- One drug costs $50 per dose. The other costs $2,000 per dose. Now, new research shows that the drug ...

The results are expected to lead many doctors and patients to turn away from the pricier Lucentis and instead use $50 shots of Avastin for an age-related condition called wet macular degeneration.

Hadassah Medical Center in Jerusalem announced that last week, an eye infection (inflammation) was detected in 11 patients who were treated with an injection of Avastin.

Dear Dr. Roach: I was diagnosed with stage 1 bladder cancer in April. My urologist advised me to have BCG therapy for it. I just completed six weeks of the therapy. I also have macular degeneration in ...

November 18, 2011 — The US Food and Drug Administration (FDA) announced today that it is rescinding its approval of bevacizumab (Avastin, Genentech) for treating metastatic breast cancer because the ...